WAM
ACIU icon

Wolverine Asset Management’s AC Immune ACIU Stock Holding History

Wolverine Asset Management’s Portfolio ACIU Stock Details ACIU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-60,000
Closed -$988K – 1163
2016
Q3 		$988K Buy
+60,000
New +$1.04M 0.01% 568

Other funds holding ACIU

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DFO
Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return
HIM
Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AA
ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Wolverine Asset Management's ACIU Position: Q4 2016 in Review

Wolverine Asset Management sold out of AC Immune (ACIU) in Q4 2016, closing a stake of 60,000 shares — an estimated $988K sold.

Wolverine Asset Management first reported a position in ACIU in Q3 2016 and held it in 1 quarter. The position peaked at $988K in Q3 2016. 19 funds tracked by Wall St. Rank hold ACIU as of Q4 2016.

  • Wolverine Asset Management reported no remaining AC Immune position as of Q4 2016 after selling out during the quarter.
  • Wolverine Asset Management sold 60,000 AC Immune shares in Q4 2016, an estimated $988K.
  • Wolverine Asset Management first reported a position in AC Immune in Q3 2016 and held it in 1 quarter.
  • Wolverine Asset Management's AC Immune position peaked at $988K in Q3 2016.
  • 19 funds tracked by Wall St. Rank held AC Immune as of Q4 2016.

Based on Wolverine Asset Management's 13F filing for Q4 2016, filed 13 Feb 2017.